ConductScience.org, home

Paper17536870

Clinical pharmacology study of Bramitob, a tobramycin solution for nebulization, in comparison with Tobi.

Poli G and 6 others. Paediatr Drugs, 2007. Cited by 23 papers, by iCite.

Cite this record

ConductScience Library. Clinical pharmacology study of Bramitob, a tobramycin solution for nebulization, in comparison with Tobi. Papers, record 17536870. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17536870

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Clinical pharmacology study of Bramitob, a tobramycin solution for nebulization, in comparison with Tobi.
PubMed
Journal
Paediatr Drugs
PubMed
Year
2007
PubMed
Publication types
Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
23
iCite
Relative citation ratio, by iCite
0.84
iCite
Revised in PubMed
2026-10-11
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Poli GGianluigi
2Acerbi DDaniela
3Pennini RRoberto
4Soliani Raschini AAnnamaria
5Corrado MEMario Ermanno
6Eichler HGHans Georg
7Eichler IIrmgard

Source PubMed

Download CSV of authors

Topics18

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Anti-Bacterial AgentsMajor topic
Cystic FibrosisMajor topic
Pseudomonas InfectionsMajor topic
TobramycinMajor topic
Administration, Inhalation
Adolescent
Adult
Biological Availability
Chronic Disease
Cross-Over Studies
Double-Blind Method
Female
Humans
Male
Nebulizers and Vaporizers
Particle Size
Pseudomonas aeruginosa
Therapeutic Equivalency

Source PubMed

Download CSV of topics

References15

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
19155846Current best practice for nebuliser treatment. The Nebulizer Project Group of the British Thoracic Society Standards of Care Committee.Thorax1997https://conductscience.org/library/papers/9155846PubMed
217536872A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study.Paediatr Drugs2007https://conductscience.org/library/papers/17536872PubMed
33931522Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum.Am Rev Respir Dis1985https://conductscience.org/library/papers/3931522PubMed
411555566Microbiological and immunologic considerations with aerosolized drug delivery.Chest2001https://conductscience.org/library/papers/11555566PubMed
514555458Pathophysiology and management of pulmonary infections in cystic fibrosis.Am J Respir Crit Care Med2003https://conductscience.org/library/papers/14555458PubMed
66696320Alteration in osmolarity of inhaled aerosols cause bronchoconstriction and cough, but absence of a permeant anion causes cough alone.Am Rev Respir Dis1984https://conductscience.org/library/papers/6696320PubMed
711568993Efficacy and safety of aerosolized tobramycin in cystic fibrosis.Pediatr Pulmonol2001https://conductscience.org/library/papers/11568993PubMed
817224667Pseudomonas aeruginosa chronic colonization in cystic fibrosis patients.Curr Opin Pediatr2007https://conductscience.org/library/papers/17224667PubMed
99366574Ion composition of airway surface liquid of patients with cystic fibrosis as compared with normal and disease-control subjects.J Clin Invest1997https://conductscience.org/library/papers/9366574PubMed
1010678295Aerosolized antimicrobial therapy in acutely ill patients.Pharmacotherapy2000https://conductscience.org/library/papers/10678295PubMed
1112114362Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis.Chest2002https://conductscience.org/library/papers/12114362PubMed
1216401680Barriers to treatment adherence for children with cystic fibrosis and asthma: what gets in the way?J Pediatr Psychol2006https://conductscience.org/library/papers/16401680PubMed
138657217Management of pulmonary disease in patients with cystic fibrosis.N Engl J Med1996https://conductscience.org/library/papers/8657217PubMed
1410492286Use of aerosolized antibiotics in patients with cystic fibrosis.Chest1999https://conductscience.org/library/papers/10492286PubMed
1517536871Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa.Paediatr Drugs2007https://conductscience.org/library/papers/17536871PubMed

Download CSV of references

Cited by10

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 23 citations.

PMIDTitleJournalYearIn PapersSource
36373968Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis.Cochrane Database Syst Rev2022https://conductscience.org/library/papers/36373968PubMed
35914011Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis.Cochrane Database Syst Rev2022https://conductscience.org/library/papers/35914011PubMed
33486720Pharmacokinetic and Pharmacodynamic Optimization of Antibiotic Therapy in Cystic Fibrosis Patients: Current Evidences, Gaps in Knowledge and Future Directions.Clin Pharmacokinet2021https://conductscience.org/library/papers/33486720PubMed
31112621Pharmacokinetics and safety of tobramycin nebulization with the I-neb and PARI-LC Plus in children with cystic fibrosis: A randomized, crossover study.Br J Clin Pharmacol2019https://conductscience.org/library/papers/31112621PubMed
30376155Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis.Cochrane Database Syst Rev2018https://conductscience.org/library/papers/30376155PubMed
29607494Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis.Cochrane Database Syst Rev2018https://conductscience.org/library/papers/29607494PubMed
25893022Evidence of inhaled tobramycin in non-cystic fibrosis bronchiectasis.Open Respir Med J2015https://conductscience.org/library/papers/25893022PubMed
22915944Tobramycin administered by the TOBI(®) Podhaler(®) for persons with cystic fibrosis: a review.Med Devices (Auckl)2011https://conductscience.org/library/papers/22915944PubMed
17536872A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study.Paediatr Drugs2007https://conductscience.org/library/papers/17536872PubMed
17536871Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa.Paediatr Drugs2007https://conductscience.org/library/papers/17536871PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/17536870

GET https://conductscience.org/api/papers/v1/17536870/authors